Success Metrics

Clinical Success Rate
88.9%

Based on 16 completed trials

Completion Rate
89%(16/18)
Active Trials
0(0%)
Results Posted
25%(4 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_1
10
53%
Ph phase_2
2
11%
Ph early_phase_1
1
5%

Phase Distribution

11

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
10(76.9%)
Phase 2Efficacy & side effects
2(15.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

84.2%

16 of 19 finished

Non-Completion Rate

15.8%

3 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(16)
Terminated(3)

Detailed Status

Completed16
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (7.7%)
Phase 110 (76.9%)
Phase 22 (15.4%)

Trials by Status

completed1684%
terminated211%
withdrawn15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT00540982Phase 1

Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction

Completed
NCT00898508

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

Completed
NCT00504296Phase 1

SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Completed
NCT01582009Phase 1

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Terminated
NCT01673217Phase 1

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed
NCT00645710Phase 1

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Completed
NCT00601913Early Phase 1

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Completed
NCT01234740Phase 1

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

Completed
NCT00547131Phase 1

Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors

Completed
NCT00825201Phase 1

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Completed
NCT00813878

Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease

Terminated
NCT01385150

Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

Completed
NCT00899769

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

Completed
NCT00664781Phase 2

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Completed
NCT01387724

Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma

Completed
NCT00753207Phase 1

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

Completed
NCT00898378

Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps

Completed
NCT00738335Phase 1

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

Withdrawn
NCT00633750Phase 2

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Completed

All 19 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
19